Oncolix, Inc., Announces Approval for Listing on OTC-QB
December 18 2017 - 4:10PM
Oncolix, Inc., (OTC PINK:ONCX) announced today that the Company has
been given approval by the OTC Markets to be listed and traded on
the OTC-QB effective at the opening of trading on December 19,
2017.
“Our listing on the OTC-QB marks the end of the
Company’s transition from Advanced Environmental Petroleum
Producers (AEPP) to Oncolix, which has included our merger into
AEPP, stock ticker and name change, new additions to the Company’s
Board of Directors and an extensive review process by the Financial
Industry Regulatory Authority (FINRA),” said Michael T. Redman,
chief executive officer of Oncolix. “Completion of these objectives
will now allow us to shift our focus toward advancing our
clinical-stage asset, Prolanta™ in development for ovarian cancer.
The next phase in the Company’s development will also be, to
continue strengthening our public company infrastructure including
the creation of a Scientific/Clinical Advisory board. This will be
crucial in providing guidance for the continued development of
Prolanta™ through the clinical trial process as well as advancing
future therapeutic candidates.”
About Oncolix
Oncolix is a clinical-stage biotechnology
company developing Prolanta™ for the treatment of ovarian, uterine,
breast and other cancers. The Company has a US FDA-cleared IND to
commence human testing of Prolanta™ in its first indication, the
treatment of ovarian cancer. This Phase 1 clinical trial is
currently in progress. Prolanta™ is a prolactin receptor antagonist
(or blocker) that has demonstrated efficacy in xenograft models
through a unique mechanism of action, autophagy. In addition to
ovarian cancer, there is strong preclinical evidence Prolanta™ may
be effective in breast, prostate and other cancers. In the current
Phase 1 dose-escalation safety trial for the treatment of ovarian
cancer, to date there have been no observed serious adverse events
and no dose-limiting toxicities. The FDA has approved the
designation of Prolanta™ as an Orphan Drug for the treatment of
ovarian cancer, which may result in reduced filing fees (currently
$2 million), federal tax credits and marketing exclusivity.
Forward-Looking Statements
This press release above may contain
forward‐looking statements about the business, financial condition
and prospects of the Company. Forward looking statements can be
identified by the use of forward-looking terminology such as
“believes,” “projects,” “expects,” “may,” “goal,” “estimates,”
“should,” “plans,” “targets,” “intends,” “could,” or “anticipates,”
or the negative thereof, or other variations thereon, or comparable
terminology, by discussions of strategy or objectives.
Forward-looking statements relate to anticipated or expected
events, activities, trends or results. Because
forward-looking statements relate to matters that have not yet
occurred, these statements are inherently subject to risks and
uncertainties.
Although the Company believes that the
expectations reflected in forward-looking statements are
reasonable, there can be no assurances that such expectations will
prove to be accurate. Security holders are cautioned that
such forward-looking statements involve risks and uncertainties.
The forward-looking statements contained in the press release speak
only as of the date of the press release, and the Company expressly
disclaims any obligation or undertaking to report any updates or
revisions to any such statement to reflect any change in the
Company’s expectations or any change in events, conditions or
circumstances on which any such statement is based. Certain factors
may cause results to differ materially from those anticipated by
some of the statements made in the press release. Investors are
urged to consider closely the disclosures in our Forms 10-K, 10-Q,
8-K and other filings with the SEC, which can be electronically
accessed from the SEC's website at http://www.sec.gov/.
Corporate contact:
Michael RedmanP: 281-402-3167E: mredman@oncolixbio.com
Investor contact:The Ruth GroupRobert Flamm, Ph.D.P:
646-536-7017E: rflamm@theruthgroup.com